Related Experiment Videos
[A clinical evaluation of aspoxicillin in children]
Insights
Aspoxicillin (ASPC), a new penicillin, effectively treated bacterial infections in children, eradicating pathogens like Streptococcus pneumoniae. No significant side effects were observed in this pediatric infectious disease study.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Therapy
Context:
- Infectious diseases pose a significant threat to infants and children.
- Development of new antimicrobial agents is crucial for combating resistant pathogens.
- Semisynthetic penicillins offer potential therapeutic advantages.
Purpose:
- To evaluate the efficacy and safety of aspoxicillin (ASPC) in pediatric patients with infectious diseases.
- To assess the pharmacokinetic profile of ASPC following intravenous administration.
- To determine the bactericidal activity of ASPC against common bacterial pathogens.
Summary:
- Aspoxicillin (ASPC) demonstrated excellent or good clinical response in 11 out of 18 pediatric patients with bacterial infections.
- ASPC successfully eradicated Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus from clinical isolates.
- Pharmacokinetic studies showed rapid absorption, with mean serum concentrations peaking at 73.3-136.3 µg/mL and half-lives around 1.07-1.08 hours.
- High urinary recovery rates (73.7-79.6%) indicate favorable renal excretion of ASPC.
- No significant clinical side effects were reported, though a transient increase in platelets was noted in one case.
Impact:
- Aspoxicillin (ASPC) shows promise as a safe and effective antibiotic for treating pediatric bacterial infections.
- The favorable pharmacokinetic and bactericidal profile supports further clinical investigation of ASPC.
- This study contributes valuable data on a novel semisynthetic penicillin for pediatric use.
Abstract:
Eighteen infants and children with infectious diseases were treated with aspoxicillin (ASPC), a new semisynthetic penicillin. The result was as follows: The clinical responses to ASPC were excellent in 6 patients and good in 5 patients of 11 children with bacterial infections. The bacteria isolated from the culture of throat swab and urine in 5 patients were Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus which were all eradicated by the treatment of ASPC. The mean serum concentration of ASPC reached the peaks of 73.3 micrograms/ml in 5 cases with dose of 20 mg/kg, and 136.3 micrograms/ml in 3 cases with dose of 40 mg/kg 15 minutes after the intravenous administration. The mean half-lives of ASPC in the serum were 1.08 hours for the dose of 20 mg/kg and 1.07 hours for the dose of 40 mg/kg. The mean urinary recoveries of ASPC in 6 hours following the intravenous administration were 73.7% in 3 cases with dose of 20 mg/kg, and 79.6% in 1 case with dose of 40 mg/kg. No clinical side effect of ASPC was observed. An increase of platelet was noticed in a child with infectious mononucleosis in the course of administration of ASPC.